Adalvo announces the partial completion of an acquisition of a pharmaceutical portfolio from Sandoz, comprising four well-established branded products, across more than 60+ markets.
With the partial completion of this acquisition, Adalvo acquires four key brands, making it the only B2B pharmaceutical company to operate across three strategic pillars - brands, complex generics, and 505(b)(2) products.
The transaction marks a significant step forward in Adalvo’s mission to build a high-performing, diversified B2B platform.
These assets extend Adalvo’s reach across several therapeutic areas - including Respiratory, Central Nervous System (CNS), Cardiovascular and Allergy, while reinforcing its branded infrastructure and global distribution capabilities. The portfolio will now organically contribute to Adalvo’s strategy to build long-term value through selective, high-return acquisitions.
The assets include over 130 marketing authorisations worldwide. Adalvo will assume full responsibility for lifecycle management, regulatory oversight, supply continuity, and commercialisation through an established partner network.
“This expansion reflects our disciplined focus on scaling high-value assets in areas where we can deliver commercial impact quickly.” said Anil Okay, CEO of Adalvo. “With the partial completion of this acquisition, we strengthen our branded presence and reinforce our position as a leading B2B growth platform.”
The newly acquired portfolio of assets complements Adalvo’s global pipeline and supports its strategy to deliver long-term value through selective, high-impact acquisitions.
To explore partnership opportunities within Adalvo’s branded portfolio, contact the team today.